Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate Mofetil

Completed

Conditions studied: Systemic Sclerosis

In brief

The purpose of this study is to assess whether skin biopsy specimens from patients with diffuse cutaneous systemic sclerosis (dcSSc) can be used as biomarkers (measures of activity and type) of disease to predict response to various experimental treatments. There are various experimental treatments being used in the treatment of slceroderma, but there is no way to predict response to any given therapy. The investigators will use DNA microarray to analyze the changes in gene expression in skin biopsies in response to various treatments. Our hypothesis is that the investigators will see changes in gene expression in response to various treatments that will give us insight into the cause of scleroderma. The investigators predict that they will be able to use this information to predict which experimental treatments will be beneficial to individual patients

Key facts

Study ID

NCT00853788

Run by

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

People needed

40

Starts

2008-11-01

Expected to finish

2011-06-01

Last updated by the study team

2012-02-17

Who can join

Age: 19 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age
• systemic sclerosis

You may not qualify if…

• pregnant
• bleeding disorder
• history of delayed wound healing

Where it is running

• Northwestern Memorial Faculty Foundation — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.